Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of IGSC 20% (Cuvitru) in Japanese PID patients
NCT04842643Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in primary immunodeficiency disease (PID), sponsored by Takeda. Started Apr 2021; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT04842643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842643.